IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. Issue 177 (May 2019)

• Record Type: Journal Article
• Authors: Tonello, Marta; Mattia, Elena; Favaro, Maria; Del Ross, Teresa; Calligaro, Antonia; Salvan, Elisa; Hoxha, Ariela; Fedrigo, Marny; Ruffatti, Amelia
• Is Part Of: Thrombosis research. Issue 177(2019)
• Page Start: 157
• Page End: 160
• Publication Date: 2019-05
• Subjects: Anti-phosphatidylserine/prothrombin antibodies -- Antiphospholipid antibody carriers -- Antiphospholipid antibodies -- Antiphospholipid antibody syndrome -- Thrombosis; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2019.03.006
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: The clinical significance of IgG/IgM antiphosphatidylserine/prothrombin (aPS/PT) antibodies was prospectively evaluated in a cohort of 191 antiphospholipid antibody (aPL) carriers using commercial ELISA assays. IgG aPS/PT antibodies were detected in 40 (20.9%) and IgM aPS/PT in 102 (53.4%) of the carriers. Both IgG and IgM aPS/PT antibodies were significantly associated with triple aPL positivity (Lupus anticoagulants [LAC] plus anti-β2Glycoprotein I plus anticardiolipin antibodies) ( p = 0.0000 for both). There was a significant prevalence of IgM aPS/PT in the individuals with isolated LAC positivity ( p = 0.005). Fourteen of the aPL carriers (7.3%) developed a first thrombotic event. There was a significant prevalence of IgG aPS/PT antibodies but not of IgM aPS/PT in the thrombotic patients ( p = 0.015). The cumulative incidence rate of thrombotic events was significantly higher in the IgG aPS/PT positive ( p = 0.035) but not in the IgM aPS/PT positive carriers. Logistic regression analysis assessing the independent effect of IgG /IgM aPS/PT antibodies, triple aPL positivity, genetic/acquired thrombosis risk factors and autoimmune disorders on thrombosis development uncovered a significant association only for the risk factors (Odds Ratio = OR: 12.451, 95% Confidence Interval = CI: 2.519–61.537, p = 0.002) and for triple aPL positivity (OR: 4.725, 95% CI: 1.135–19.674, p = 0.033). Logistic regression evaluating the independent effect of IgG and IgM aPS/PT on thrombosis development uncovered a significant association only for the former (OR: 3.962, 95% CI: 1.174–13.37, p = 0.026). The risk score for thrombosis in aPL carriers could be more effective if IgG aPS/PT antibodies are added to triple aPL positivity and thrombosis risk factors. Highlights: The predictivity for thrombosis of IgG/IgM aPS/PT test was evaluated in aPL carriers. IgG but not IgM aPS/PT antibodies significantly prevailed in aPL carriers who developed thrombosis. IgG aPS/PT antibodies could improve the risk score for thrombosis in aPL carriers.